Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. by Huizinga, TW, Holers, VM, Anolik, J, Brenner, MB, Buckley, CD, Bykerk, V, Connolly, SE, Deane, KD, Guo, J, Hodge, M, Hoffmann, S, Nestle, F, Pitzalis, C, Raychaudhuri, S, Yamamoto, K, Li, Z, Klareskog, L

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: resul... by Taylor, PC, Schett, G, Huizinga, TW, Wang, Q, Ibrahim, F, Zhou, B, Liva, SG, Shaik, JSB, Xiong, Y, Leu, JH, Panchakshari, RA, Loza, MJ, Ma, K, Dhatt, H, Rojo Cella, R, Karyekar, CS, Cuff, CA, Gao, S, Fei, K